Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort
British Journal of Clinical Pharmacology2018Vol. 85(2), pp. 403–412
Citations Over TimeTop 12% of 2018 papers
Florence Daviet, Franck Rouby, Pascale Poullin, Julie Moussi‐Francès, Marion Sallée, Stéphane Burtey, Julien Mancini, Florence Duffaud, Renaud Sabatier, Bertrand Pourroy, Aurélie Grandvuillemin, Steven Grangé, Véronique Frémeaux‐Bacchi, Paul Coppo, Joëlle Micallef, Noémie Jourde‐Chiche
Abstract
This large cohort confirms the severity of G-TMA, associated with severe renal failure and death. Oedema and hypertension could be monitored in patients treated with gemcitabine to detect early TMA. The benefit of PE or eculizumab deserves further investigation.
Related Papers
- → Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy(2015)132 cited
- → Two cases of kidney transplantation‐associated thrombotic microangiopathy successfully treated with eculizumab(2016)27 cited
- → The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome(2020)18 cited
- → Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy(2021)7 cited
- → An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report(2015)8 cited